Aileron Therapeutics is a biotechnology company focused on the development of innovative drug therapies that leverage its proprietary platform for the design of stapled peptides

These therapies are aimed at treating a range of serious diseases, including cancer and other conditions characterized by protein-protein interactions. By stabilizing the structure of peptides, the company enhances their ability to engage specific biological targets, with the goal of improving patient outcomes through more effective treatments. Aileron's commitment to advancing therapeutic options is supported by robust research and collaborations within the scientific community.